DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5k7jth/pharmapoint) has announced the addition of the "PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022" report to their offering.
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab). The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
In contrast to the 7MM, but akin to Canada, Remicade will remain on patent in the Japanese CD market for a significant portion of the 10-year forecast period, with biosimilar erosion predicted from 2021 on. This, in turn, will lead to the brand experiencing year-on-year growth through to its peak-year sales in 2022.
Key Topics Covered:
- Tables & Figures
- Disease Overview
- Disease Management
- Competitive Assessment
- Opportunity and Unmet Need
- Pipeline Assessment
- Market Outlook
For more information visit http://www.researchandmarkets.com/research/5k7jth/pharmapoint